HC Wainwright Reaffirms Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)

HC Wainwright restated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report published on Monday, MarketBeat reports. HC Wainwright currently has a $73.00 target price on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $2.09 EPS.

Several other equities analysts have also recently weighed in on the company. JMP Securities lifted their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a “market outperform” rating in a research note on Friday, May 9th. Raymond James reaffirmed a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. Finally, Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $60.73.

Mirum Pharmaceuticals Trading Down 2.3%

Shares of MIRM opened at $44.31 on Monday. The business’s 50-day moving average price is $42.98 and its 200 day moving average price is $44.55. The stock has a market capitalization of $2.19 billion, a P/E ratio of -21.94 and a beta of 0.95. Mirum Pharmaceuticals has a 1-year low of $23.83 and a 1-year high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $111.59 million for the quarter, compared to analysts’ expectations of $98.47 million. During the same quarter last year, the business posted ($0.54) EPS. Mirum Pharmaceuticals’s revenue was up 61.2% on a year-over-year basis. Analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Activity

In related news, CEO Christopher Peetz sold 27,279 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jolanda Howe sold 57,606 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the sale, the senior vice president now owns 4,841 shares of the company’s stock, valued at approximately $214,698.35. This trade represents a 92.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 92,764 shares of company stock worth $4,109,161 in the last three months. 14.36% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Barclays PLC lifted its holdings in Mirum Pharmaceuticals by 4.6% in the 3rd quarter. Barclays PLC now owns 245,918 shares of the company’s stock worth $9,592,000 after purchasing an additional 10,824 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $189,000. Secure Asset Management LLC boosted its position in shares of Mirum Pharmaceuticals by 9.3% in the fourth quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock valued at $1,651,000 after acquiring an additional 3,406 shares during the period. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $69,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after acquiring an additional 1,003 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.